Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 27;24(1):540.
doi: 10.1186/s12866-024-03692-9.

Advancements in MRSA treatment: the role of berberine in enhancing antibiotic therapy

Fangfang Zhou #  1   2 , Xuemei Gu #  1 , Wei Wang  1 , Ming Lin  1 , Lei Wang  3
Affiliations

Advancements in MRSA treatment: the role of berberine in enhancing antibiotic therapy

Fangfang Zhou et al. BMC Microbiol. .

Abstract

Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a significant public health problem. This study investigated the antimicrobial properties and mechanisms of berberine (BBR), a plant alkaloid, against MRSA, evaluating its potential to enhance antibiotic therapy.

Results: Berberine only demonstrated variable but significant inhibitory effects on 50 clinical MRSA strains. When combined with antibiotics, synergistic effects were observed only with amikacin in 6 of the 50 MRSA strains. BBR disrupted MRSA cell wall integrity, leading to leakage of cellular contents. Network pharmacology analysis revealed that BBR targets multiple pathways essential for bacterial survival.

Conclusion: The study confirmed the potent antimicrobial activity of berberine against MRSA and its capability to act synergistically with traditional antibiotics. Berberine's impact on cell wall integrity and bacterial survival pathways highlights its potential as an adjunct therapy in MRSA treatment.

Keywords: Berberine; Cell wall damage; Methicillin-resistant Staphylococcus aureus; Minimum inhibitory concentration; Network pharmacology.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This study, isolating MRSA strains from clinical patient samples, adhered to strict ethical guidelines for clinical research. The study strictly followed the Declaration of Helsinki, and ethics approval was obtained from the Ethics Committee of Shanghai Eighth People’s Hospital (Approval Number: 2023-058-18). All participating patients provided written informed consent. Conflict of interest: The author declares no conflict of interest.

Figures

Fig. 1
Fig. 1
Susceptibility test results of 50 MRSA strains against 12 antibiotics. Note: Red indicates resistance (R: Resistance), yellow indicates intermediate sensitivity (I: Intermediary), and blue indicates sensitivity (S: Sensitivity). Most MRSA strains exhibited high sensitivity to vancomycin and linezolid while showing near-complete resistance to penicillin G
Fig. 2
Fig. 2
Bar graphs illustrating the effects of different concentrations of BBR on the proliferation of MRC-5 and FHC cells. Note: (A) The effect of different concentrations of BBR on the proliferation of MRC-5 cells. (B) The effect of different concentrations of BBR on the proliferation of FHC cells. Below a concentration of 64 µg/mL, BBR did not cause a significant impact on cell proliferation. (Compared to the control group, ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05; ns: not statistically significant)
Fig. 3
Fig. 3
Time-kill curves of MRSA2022 treated with different concentrations of BBR in combination with three antibiotics. Note: (A) The antibacterial effect of BBR in combination with GEN on MRSA2022. (B) The antibacterial effect of BBR in combination with LEV on MRSA02. (C) The antibacterial effect of BBR in combination with AMI on MRSA2022
Fig. 4
Fig. 4
Study on the impact of BBR on the permeability and viability of MRSA cell membranes. Note: (A) Illustrates the effect of different concentrations of BBR on the conductivity of the culture medium for the MRSA2202 strain, reflecting the disruption of bacterial cell membrane integrity. (B) Flow cytometry analysis demonstrates the percentage of live and dead bacteria in the USA300 strain after treatment with BBR, highlighting its bactericidal efficacy
Fig. 5
Fig. 5
TEM observation of the MRSA2202 strain cell wall at 80,000x magnification. Note: (A) Low concentration (8 µg/mL) of BBR shows no apparent damage to the cell wall; red arrows point to the deposition of BBR crystals around the bacterial cell wall, with black crystalline material being BBR. (B) At high concentrations (512 µg/mL), there is significant damage to the cell wall structure and bacterial dissolution. Red arrows indicate the severe destruction and dissolution of the bacterial cell wall under high-concentration BBR treatment, along with extensive leakage of cellular contents, leading to bacterial lysis and death. (Microscope H-7650, acceleration voltage 80 kV)
Fig. 6
Fig. 6
Network analysis of targets and signaling pathways of BBR in the treatment of MRSA. Note: (A) Number and characteristics of interactions between BBR and MRSA-related targets. (B) Interrelationships between BBR and essential biomolecules in MRSA through PPI network analysis. (C) Network visualization analysis of core genes, identifying critical genes related to MRSA survival and pathogenicity potentially affected by BBR. (D) KEGG enrichment analysis of the MRSA-related biological pathways influenced by BBR. (E) GO analysis of the biological processes, cellular components, and molecular functions impacted by BBR. Graphical abstract Illustration of the antimicrobial mechanism of BBR against MRSA
See this image and copyright information in PMC

References

    1. Ahmad-Mansour N, Loubet P, Pouget C, et al. Staphylococcus aureus Toxins: an update on their pathogenic properties and potential treatments. Toxins (Basel). 2021;13(10):677. 10.3390/toxins13100677. Published 2021 Sep 23. - PMC - PubMed
    1. Urish KL, Cassat JE. Staphylococcus aureus Osteomyelitis: bone, bugs, and surgery. Infect Immun. 2020;88(7):e00932–19. 10.1128/IAI.00932-19. Published 2020 Jun 22. - PMC - PubMed
    1. Löffler B, Tuchscherr L. Staphylococcus aureus Toxins: promoter or handicap during infection? Toxins (Basel). 2021;13(4):287. 10.3390/toxins13040287. Published 2021 Apr 19. - PMC - PubMed
    1. Henriquez E, Fatima N, Sayabugari R, et al. Transesophageal Echocardiography vs. Transthoracic Echocardiography for Methicillin-Sensitive Staphylococcus aureus and Methicillin-Resistant Staphylococcus aureus Endocarditis. Cureus. 2023;15(6):e39996. 10.7759/cureus.39996. Published 2023 Jun 5. - PMC - PubMed
    1. Chen TY, Ge YL, Liu XW, et al. Zhonghua Yu Fang Yi Xue Za Zhi. 2020;54(8):849–53. 10.3760/cma.j.cn112150-20190819-00669 - PubMed

MeSH terms

LinkOut - more resources